Neutralizing antibody response against variants of concern after vaccination of dialysis patients with BNT162b2

We and others showed high seroconversion rates after BNT162b2 mRNA vaccination in patients on hemodialysis, but still significantly lower rates as compared to healthy controls (1 –3). Variants of concern (VOCs) such as B.1.351 (beta variant) or B.1.617.2 (delta variant) partially escape from neutralizing antibodies (NAbs) and will probably replace wildtype SARS-CoV-2 or the B.1.1.7 (alpha) variant with increasing immunity in the population, induced by natural infection or vaccination. Wall et al.

Source: Kidney International - July 11, 2021 Category: Urology & Nephrology Authors: Claudius Speer, Louise Benning, Maximilian T öllner, Christian Nusshag, Florian Kälble, Paula Reichel, Matthias Schaier, Marie Bartenschlager, Paul Schnitzler, Martin Zeier, Caner Süsal, Christian Morath, Ralf Bartenschlager Tags: letters to the editor Source Type: research